At the first interim analysis—which is considered final for survival endpoints—the median overall survival in the intent-to-treat population reached 13.2 months for patients receiving daraxonrasib, versus 6.7 months for those treated with standard cytotoxic chemotherapy. This improvement translated to a 60% reduction in the risk of death (hazard ratio, 0.40; p < 0.0001). The therapy also produced statistically and clinically meaningful benefits in progression-free survival, meeting both primary and key secondary endpoints.

Importantly, daraxonrasib demonstrated a manageable safety profile, with no unexpected toxicities observed and tolerability consistent with earlier clinical experience.

A Major Advance for a High-Unmet-Need Population

Metastatic pancreatic cancer remains an area of profound unmet medical need, with limited effective therapies available beyond first-line chemotherapy. According to Brian M. Wolpin, MD, MPH, principal investigator of RASolute 302 and a pancreatic cancer specialist at Dana-Farber Cancer Institute, the findings represent a highly meaningful therapeutic step forward.

He noted that daraxonrasib offers a new mechanism-driven option for patients whose cancers have progressed after standard treatments, a setting where survival outcomes have historically been poor and therapeutic innovation has lagged behind other tumor types.

Targeting RAS Addiction in Pancreatic Cancer

More than 90% of pancreatic cancers are driven by mutations in RAS genes, making PDAC the most RAS-dependent of all major malignancies. These mutations activate oncogenic signaling pathways that promote aggressive tumor growth, metastasis, and resistance to therapy.

Daraxonrasib is part of a novel class of agents designed to inhibit RAS proteins in their active, signaling “ON” state. Unlike earlier RAS-targeted strategies that focused on single mutant variants, daraxonrasib is engineered to broadly suppress signaling from multiple mutant and wild-type RAS proteins.

RASolute 302 enrolled patients with a wide spectrum of RAS alterations, including common G12 variants such as G12D, G12V, and G12R, as well as a subset of patients without an identifiable RAS mutation. The trial’s primary efficacy analyses focused on patients with RAS G12–mutant tumors, while secondary analyses assessed outcomes in the entire study population.

Trial Design and Regulatory Plans

RASolute 302 is an ongoing, randomized Phase 3 registrational trial comparing once-daily oral daraxonrasib (300 mg) with investigator’s choice of standard chemotherapy. In addition to overall and progression-free survival, the study evaluates objective response rates, durability of response, and patient-reported quality-of-life outcomes.

Based on the robustness of the interim results, Revolution Medicines plans to incorporate the data into a future New Drug Application submission to the U.S. Food and Drug Administration, as well as to regulatory agencies worldwide. The company intends to pursue review under the FDA’s Commissioner’s National Priority Voucher program and to present detailed findings at the 2026 American Society of Clinical Oncology Annual Meeting.

Daraxonrasib has already received FDA Breakthrough Therapy and Orphan Drug designations for previously treated metastatic PDAC with RAS G12 mutations, reflecting its potential clinical importance.

Implications for the Treatment Landscape

Mark A. Goldsmith, MD, PhD, chief executive officer of Revolution Medicines, described the trial outcomes as potentially transformative, emphasizing their potential to redefine treatment expectations for metastatic pancreatic cancer. He also highlighted the broader implications for RAS-driven malignancies, noting that daraxonrasib is being evaluated across four Phase 3 programs, including studies in non-small cell lung cancer.

The success of RASolute 302 further validates a long-term scientific strategy focused on RAS(ON) inhibition, an approach developed over more than a decade of foundational research.

If regulatory approvals follow, daraxonrasib could become the first broadly effective RAS-targeted therapy to meaningfully extend survival in pancreatic cancer—offering new hope in a disease long defined by limited options and poor outcomes.